|
|
| | METHYSTICIN Basic information |
| Product Name: | METHYSTICIN | | Synonyms: | 5,6-Dihydro-4-methoxy-6-(3,4-(methylenedioxy)styryl)-2H-pyran-2-one;METHYSTICIN;KAVAHIN;KAVATIN;(±)-Methystici);Methysticin (DL-Methysticin;2H-Pyran-2-one, 6-[(1E)-2-(1,3-benzodioxol-5-yl)ethenyl]-5,6-dihydro-4-methoxy-;METHYSTICIN USP/EP/BP | | CAS: | 20697-20-5 | | MF: | C15H14O5 | | MW: | 274.27 | | EINECS: | | | Product Categories: | | | Mol File: | 20697-20-5.mol |  |
| | METHYSTICIN Chemical Properties |
| Melting point | 129-131 °C | | Boiling point | 496.5±45.0 °C(Predicted) | | density | 1.31±0.1 g/cm3(Predicted) |
| | METHYSTICIN Usage And Synthesis |
| Uses | DL-Methysticin is a useful synthetic compound. | | in vivo | The kavalactone Methysticin (6 mg/kg) is administered once a week for a period of 6 months to 6 month old transgenic APP/Psen1 mice by oral gavage. Methysticin treatment activates the Nrf2 pathway in the hippocampus and cortex of mice. The Aβ deposition in brains of Methysticin-treated APP/Psen1 mice is not altered compared to untreated mice. However, Methysticin treatment significantly reduces microgliosis, astrogliosis and secretion of the pro-inflammatory cytokines TNF-α and IL-17A. Methysticin treatment results in a significant activation of the Nrf2/ARE pathway in hippocampus and the cortex but not in the midbrain and cerebellum of ARE-luciferase reporter gene mice. Methysticin treatment significantly increases the expression of both genes compared to untreated animals[2]. | | IC 50 | CYP1A1 |
| | METHYSTICIN Preparation Products And Raw materials |
|